Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 7,669 | 19,569 | 12,700 | 13,789 | 8,601 |
| Gross Profit | 7,669 | 19,569 | 12,700 | 13,789 | 8,601 |
| Operating Expenses | 52,579 | 37,371 | 25,274 | 20,926 | 24,099 |
| Operating Income | -44,910 | -17,802 | -12,574 | -7,137 | -15,498 |
| Interest Expense | 39 | 36 | 247 | 388 | 362 |
| Other Income | -11,730 | -853 | -4,597 | 129 | 271 |
| Pre-tax Income | -56,679 | -18,691 | -17,418 | -7,396 | -15,589 |
| Income Tax | 1 | -23 | -10 | 206 | -30 |
| Net Income Continuous | -56,680 | -18,668 | -17,408 | -7,602 | -15,559 |
| Net Income | $-56,680 | $-18,668 | $-17,408 | $-7,602 | $-15,559 |
| EPS Basic Total Ops | -154.86 | -58.82 | -254.50 | -10,302.52 | N/A |
| EPS Basic Continuous Ops | -154.33 | -58.24 | -254.45 | -10,253.99 | N/A |
| EPS Diluted Total Ops | -154.86 | -58.82 | -254.50 | -10,302.52 | N/A |
| EPS Diluted Continuous Ops | -154.33 | -58.24 | -254.45 | -10,253.99 | N/A |
| EBITDA(a) | $-41,823 | $-15,003 | $-11,163 | $-5,675 | $-14,482 |